Author:
Pagani O.,Klingbiel D.,Ruhstaller T.,Nolè F.,Eppenberger S.,Oehlschlegel C.,Bernhard J.,Brauchli P.,Hess D.,Mamot C.,Munzone E.,Pestalozzi B.,Rabaglio M.,Aebi S.,Ribi K.,Rochlitz C.,Rothgiesser K.,Thürlimann B.,von Moos R.,Zaman K.,Goldhirsch A.
Reference15 articles.
1. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline;Giordano;J Clin Oncol,2014
2. Targeted therapy in her2-positive metastatic breast cancer: a review of the literature;Zhu;Curr Oncol,2015
3. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3);Cardoso;Ann Oncol,2016
4. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015
5. Trastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study;Wildiers,2015
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献